• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . Symptom burden, viral load, and antibody response to ancestral SARS-CoV-2 strain [D614G] in an outpatient household cohort

tetano

Editor, Senior Moderator
PLoS One


. 2026 Feb 5;21(2):e0313467.
doi: 10.1371/journal.pone.0313467. eCollection 2026.
Symptom burden, viral load, and antibody response to ancestral SARS-CoV-2 strain [D614G] in an outpatient household cohort

Mehal Churiwal[SUP] 1 [/SUP], Kathleen Tompkins[SUP] 1 [/SUP], Gabrielle Streeter[SUP] 1 [/SUP], Christy Litel[SUP] 1 [/SUP], Sydney Mason[SUP] 1 [/SUP], Kelly Lin[SUP] 1 [/SUP], Meredith Muller[SUP] 1 [/SUP], Srijana Chhetri[SUP] 1 [/SUP], Tia Belvin[SUP] 1 [/SUP], Feng-Chang Lin[SUP] 2 [/SUP], Christopher Basham[SUP] 1 [/SUP], Maureen Whittelsey[SUP] 1 [/SUP], Tyler Rapp[SUP] 1 [/SUP], Lakshmanane Premkumar[SUP] 3 [/SUP], Carla Cerami[SUP] 4 [/SUP], Jessica T Lin[SUP] 1 3 [/SUP]


Affiliations
Abstract

Background: Early in the SARS-CoV-2 pandemic, description of COVID-19 illness among non-hospitalized patients was limited. Data from household cohorts can help reveal the full spectrum of disease and the potential for long-term sequelae, even in non-severe disease.
Methods: Daily symptom diaries were collected in a US household cohort of SARS-CoV-2 infection from April to November 2020, during the pre-COVID vaccine period. SARS-CoV-2 nasal viral loads were measured at study entry and weekly until day 21; serologic testing was performed at study entry and day 28. A subset of volunteers underwent an additional assessment 8-10 months later. Participants who met the criteria for early infection-testing antibody-negative at study entry but PCR-positive either at baseline or during follow-up-were included in this analysis (n = 143).
Results: Daily symptoms were ascertained in 143 outpatients with acute COVID-19, including 60 index cases who sought testing and 83 of their household contacts. Asymptomatic cases comprised 16% (13/83) of SARS-CoV-2 infections detected among household contacts. Among 119 persons with mild or moderate illness, the number of symptoms peaked 3 or 4 days after symptom onset. Fever and anosmia occurred in nearly half of participants. Symptom severity was associated with increased age, viral load, and cardiovascular disease. Increased BMI was associated with a higher antibody level at day 28, independent of symptom severity. Those with a higher day 28 antibody level were more likely to develop symptoms consistent with post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID-19, 8-10 months later.
Conclusions: Fever, anosmia, as well as asymptomatic infection were common features of COVID-19 non-severe illness when the D614G variant circulated in the US, before the availability of vaccines or outpatient therapies. Antibody levels following acute infection were linked to the development of symptoms of PASC 8-10 months later.


 
Back
Top